How will focal therapy fit in with existing treatments

[1]  H. Ahmed,et al.  Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. , 2013, The Journal of urology.

[2]  Eric A Singer,et al.  Gleason score 6 adenocarcinoma: should it be labeled as cancer? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Farmer,et al.  Reuse of Medical Devices and Global Health Equity , 2012, Annals of Internal Medicine.

[4]  S. Schnitt,et al.  Surgical margins in lumpectomy for breast cancer--bigger is not better. , 2012, The New England journal of medicine.

[5]  M. Lapitan,et al.  Systematic review of oncological outcomes following surgical management of localised renal cancer. , 2012, European urology.

[6]  T. H. van der Kwast,et al.  Comparison of incidentally detected prostate cancer with screen‐detected prostate cancer treated by prostatectomy , 2012, The Prostate.

[7]  N. Mottet,et al.  [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. , 2011, Actas urologicas espanolas.

[8]  G. Haber,et al.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.

[9]  Yipeng Hu,et al.  Characterizing clinically significant prostate cancer using template prostate mapping biopsy. , 2011, The Journal of urology.

[10]  J. Kepner,et al.  Transperineal prostate biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies , 2010, Theoretical Biology and Medical Modelling.

[11]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[12]  Laurent Lemaitre,et al.  Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance , 2009, Current opinion in urology.

[13]  A. Evans,et al.  Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. , 2007, Contemporary clinical trials.

[14]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[15]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.